Savara is on track for potential approval by the end of 2025 for MOLBREEVI™s in autoimmune pulmonary alveolar proteinosis (aPAP), assuming the treatment receives priority review. The company has ...

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price ...

at 08:40 Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research ...

Valley Oaks Health, an Indiana Certified Community Mental Health Center serving the behavioral health and primary care needs of nearly 12,000 people each year, and a member of The Indiana ...

No extract is available for articles shorter than 400 words.

Pulmonary alveolar proteinosis (PAP) is a rare phenotype of IARS1 deficiency, having been reported in only two siblings from the same family. In this study, we present a case of IARS1 deficiency in a ...

Clear accumulated neurotoxic materials; Reduce extracellular matrix (ECM) contents around the heart injury site; Resolve the pathology of pulmonary alveolar proteinosis (PAP); Coordinate the ...